Product Description
Ferric citrate (FC) is an iron-containing phosphate binder that has been shown to effectively decrease serum phosphate, increase hemoglobin, and replete iron stores in patients with chronic kidney disease. Intestinal absorption of iron from FC results in increases in serum iron, ferritin, and transferrin saturation, effects that occur over 12 to 24 weeks and subsequently appear to plateau. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/27236135/)
Mechanisms of Action: TFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Bangladesh | Belgium | Brazil | European Medicines Agency | Hungary | Ireland | Italy | Japan | Latvia | Lithuania | Pakistan | Poland | Portugal | Sweden | Switzerland | Taiwan | Turkey | United States
Approved Indications: None
Known Adverse Events: None
Company: Akebia
Company Location: Eastern America
Company Founding Year: 2012
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Bangladesh, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Anemia|Anemia, Iron-Deficiency|Hyperphosphatemia|Kidney Failure, Chronic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07381426 |
IRB-DMC/2025/291 | P3 |
Not yet recruiting |
Anemia |
2026-12-31 |
2026-02-03 |
Primary Endpoints |
|
NCT04523727 |
KRX-0502-308 | P3 |
Suspended |
Kidney Failure, Chronic|Hyperphosphatemia |
2026-12-01 |
22% |
2026-02-18 |
|
NCT05085275 |
FRONTIER | P3 |
Completed |
Hyperphosphatemia|Anemia, Iron-Deficiency|Kidney Failure, Chronic |
2024-01-24 |
14% |
2025-08-27 |
Primary Endpoints|Treatments |